Post-transplant Diabetes Mellitus
10
1
2
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
50%
5 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (10)
Silymarin's Advantage on Graft Effectiveness
Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
SGLT2i in Diabetic Patients with Renal Transplantation
Define Predictors for Posttransplant Diabetes Mellitus Study
Tacrolimus Formulation and Glucose Metabolism After Kidney Transplantation (TAGLUMET Trial)
Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant
The POWERED Study: Prophylaxis With Metformin to Prevent PTDM
Empagliflozin in Post-Transplantation Diabetes Mellitus
GLP-1 Effects on Insulin and Glucagon in PTDM
Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients